Canine pancreatitis remains a clinical challenge due to its varied presentation, complex pathophysiology, and potential for rapid deterioration. In this episode, we explore diagnostic strategies—including imaging and biomarker-based approaches—and review the foundational treatments of fluid therapy, analgesia, antiemetics, and nutritional support. We also highlight emerging therapies, with a focus on Panoquell-CA1 (fuzapladib sodium for injection), the first FDA conditionally approved drug designed to target inflammation in dogs with acute pancreatitis. Tune in as we unpack the science, share clinical insights, and discuss how this novel treatment may enhance multimodal care for this serious condition.